CION Ameerpet
Clinical Trials & Access
Risks of Joining an Immunotherapy Trial — Stated Plainly, Before You Consent
The main risks are side effects that are not yet fully mapped, a heavier schedule of visits and tests, and the real possibility that the treatment does not help you. A trial is a study, not a treatment plan. Knowing exactly what you are carrying is what makes the decision yours.
Medically reviewed by Dr. C. Raghavendra Reddy, Medical Oncologist, MBBS (Gold Medal) · DNB · DM (Medical Oncology, Gold Medal) · Last reviewed August 2026
- The side-effect list may be incomplete — An investigational drug is being studied because its full profile is not yet settled. The earlier the phase, the less is known.
- Expect more visits, not fewer — Screening tests, bloods before every cycle and scans on a fixed protocol calendar, plus follow-up after treatment ends.
- No result is promised to anyone — No benefit is claimed here for any investigational treatment, and no place on a study can be assured by anyone.
- Information, not recruitment — Nothing on this page is an offer of a place on a study. Read it, then take the consent document to your own oncologist.
17+
Cancer Specialists
on Panel
on Panel
96.9%
Breast Cancer
Survival Rate*
Survival Rate*
15,000+
Patients
Treated
Treated
4.8★
Google Rating
(800+ reviews)
(800+ reviews)
The direct answer
What Are the Real Risks of Joining an Immunotherapy Trial?
Four risks are real. The side-effect profile of an investigational drug may still be incomplete. The schedule is heavier than routine care. In a randomised study you may be placed in the comparison arm. And the treatment may not help you. All four are written down before you sign.
For a great many Indian families a trial is the route by which this class of treatment becomes reachable at all, and that changes how the risks get read. When the alternative is no access, the temptation is to skim the risk section and sign. The opposite is the better instinct. A study you have understood is a study you can leave, question, and hold to its own protocol; a study you signed without reading is one you carry blindly.
So this page does the unglamorous thing and states the downside first. Nothing here is an offer of a place on a study, no enrolment can be assured by anyone, and no benefit is claimed for any investigational treatment. What follows is what a family should know before the consent document is on the table.
| Risk | What it means in practice | What sits between you and it |
|---|---|---|
| Side effects that are not yet fully mapped | An investigational drug is under study precisely because its full profile is unsettled. A reaction can appear that the protocol did not anticipate | Ethics committee review before the study opens, protocol stopping rules, and a duty on the team to report and act on serious events |
| Immune-related reactions | Checkpoint treatment can inflame the gut, lungs, liver, skin, heart or hormone glands. Some of these become serious quickly | Baseline and pre-cycle bloods, a symptom-reporting line, and a standing instruction to contact the team the same day rather than wait for the next visit |
| Assignment to the comparison arm | In a randomised study a computer, not your doctor, decides your arm. You may receive standard treatment rather than the investigational drug | The consent document states the arms and your chance of each. Where a standard treatment exists, the comparison arm receives it |
| Extra procedures | Screening imaging, ECGs, additional blood panels and sometimes a research biopsy, which carries its own procedural risk | Each procedure is listed in the consent document. Ask which are required for eligibility and which are optional research add-ons |
| The treatment may not help you | No result is established for an investigational drug, and none is promised. Disease can progress on study as it can off it | Protocol-defined response assessment, and a planned route to the next standard line of treatment |
| Screening failure and delay | You can be turned down after screening tests are complete, having lost days or weeks in the process | Ask at the first meeting how long screening takes and keep a standard treatment plan alive alongside the trial question |
| The study can close, or supply can end | A sponsor can stop a study early. Continued access to the drug after the study ends is not assured | Ask for the post-study position in writing before you consent, not after the study closes |
The table is general and indicative, as of August 2026. It describes how cancer studies are commonly built and does not describe the specific study you have been offered. Only that study’s participant information sheet, consent document and registry entry describe it, and you are entitled to all three before deciding. If you develop chest pain, breathlessness, persistent loose motions, severe abdominal pain or sudden collapse while on any immunotherapy, contact the treating team immediately or go to the nearest emergency department — do not manage it at home. CION’s helpline is 1800 202 8726.
Did you know?
A clinical trial in India is not an informal arrangement between a doctor and a patient. A study of a new drug needs permission from CDSCO, clearance from a registered ethics committee, and prospective registration with the Clinical Trials Registry – India (CTRI), maintained by ICMR’s National Institute of Medical Statistics. Under the New Drugs and Clinical Trials Rules, 2019, the sponsor must provide free medical management for an injury related to the trial, and compensation is determined under that framework where an injury is attributed to the study. An illness unrelated to the trial is not covered by it.
The time cost
Will a Trial Mean Extra Visits, Scans and Blood Tests?
Yes. Almost every study asks for more than routine care. Expect a screening window with imaging and detailed bloods, tests before each cycle, response scans on fixed protocol dates, and follow-up visits after treatment ends. Some protocols also ask for a repeat research biopsy.
What the extra load usually looks like
- A screening window first — imaging, an ECG, detailed bloods and often a tissue sample, all before eligibility is confirmed.
- A fixed visit calendar — the protocol sets the dates. Routine care can flex around a wedding or a harvest; a study rarely can.
- Bloods before every cycle — usually more panels than standard care alone would order, and results must be back before treatment is given.
- Scans on protocol dates — response assessment happens on the study calendar. At CION, response-assessment PET-CT is coordinated at partner imaging centres rather than owned by us.
- Possible research biopsies — a repeat tissue sample is a procedure with its own risk. Ask whether it is required for eligibility or optional.
- Follow-up after treatment ends — visits and phone calls usually continue for a defined period written into the protocol.
Count the travel before you count the drug. For a family coming into Hyderabad from a district, the honest cost of a study is often the days away from work and the attendant who travels too, not the medicine. Put the whole calendar on paper first. Costs and arrangements described on this page are indicative, as of August 2026.
The hardest question
What Happens If the Trial Treatment Does Not Work?
You come off the study and move to the next standard option. Progression is a defined reason for participation to end, and the protocol plans for it. Coming off a study does not remove your right to treatment at that centre. Ask what the next line would be before you consent.
- Progression is planned for, not improvised — the protocol defines what counts as progression and what happens next.
- Standard treatment stays available — leaving a study, or being withdrawn from one, does not end your right to normal care.
- No result is promised to anyone — an investigational treatment is being studied because its place is not settled, and no benefit is claimed for it here.
- Ask about supply after the study — continued access once a study closes is not assured. Get the position in writing before you join.
- Know which costs change — the next line of treatment is ordinary care with ordinary costs, and the sponsor’s coverage of protocol items ends with the study.
- Tell your own oncologist the same week — whoever will treat you next needs the study records, the drug you received and the dates.
This page is information, not recruitment. Nothing here is an offer of a place on any study, no enrolment can be assured by anyone, and no benefit is claimed for any investigational treatment. Screening can end in a “no” even after the process has started, so keep a standard treatment plan alive alongside any trial question.
CION does not provide CAR-T or other cell therapies. Where a CAR-T or cell-therapy study is what is being discussed, that is a referral to a centre that runs it, and anything written here is orientation only.
12+ Centres in Hyderabad · Pick yours
CION cancer care is closer than you think.
We're never more than 30 minutes away. Same panel of specialists at every centre. Same tumour board reviews. Same NCCN protocols. Pick the closest one and call directly — or let us pick for you.
CION Ameerpet
CION Kukatpally
CION L.B. Nagar
CION Tolichowki
CION Masab Tank
CION Banjara Hills
CION Kompally
CION Balanagar
CION Siddipet
CION Sangareddy
Not sure which centre fits best? Tell us where you are — we'll suggest the closest one with the right specialists.
Help me pick the right centre
Beyond Hyderabad
35+ centres across Telangana & Andhra Pradesh
Travelling for treatment? We may have a centre right where you are.
Telangana
Andhra Pradesh
Don't see your city? Call 18002028726 — we'll find your nearest CION partner centre.
Meet the Specialists
17+ senior cancer specialists. One panel for your case.
Trained at AIIMS, Tata Memorial, and leading international centres. Combined 150+ years of experience. Every complex case is reviewed by 3+ of them — together.
Medical Oncologist
Medical Oncologist
Dr. C. Raghavendra Reddy
MBBS(Gold Medal), DNB(General Medicine), DM(Medical Oncology)(Gold Medal)
Medical Oncologist
Dr. Bharati Devi Gorantla
MBBS, MD(General Medicine), DM(Medical Oncology)(Adyar,Chennai), ECMO, MRCP SCE(UK)
Medical Oncologist
Dr. Owais Mohammed
MBBS, MD (General Medicine), DrNB (Medical Oncology), ECMO, MRCP SCE (Medical Oncology) (UK)
Medical Oncologist
Medical Oncologist
Surgical Oncologist
Dr. Muralidhar Muddusetty
MBBS (AIIMS), MS (Surgery) (AIIMS), DNB (Surgical Oncology), MRCS (Edinburgh)
Surgical Oncologist
Surgical Oncologist
Surgical Oncologist
Dr. Vinay Mamidala
MBBS, MS(General Surgery), M.Ch(Surgical Oncology), FMAS, FARIS(Ongoing)
Surgical Oncologist
Radiation Oncologist
Radiation Oncologist
Radiation Oncologist
Hematologist
Interventional Radiologist
Dr. Mohammed Imran
Surgical Oncologist
Dr. Vajja Sandeep Kumar
MBBS, MS (General Surgery), DrNB (Surgical Oncology), FALS Oncology
Surgical Oncologist
Want a specific doctor for your case? Mention them when booking.
Book Free ConsultationBook an appointment with our specialist
Share your name and number — we'll call you back within 30 minutes to schedule your consultation.
Get the Trial Risks Explained by an Oncologist
A free consultation covers the risks written into the consent document, the visit schedule a study actually demands, and what the standard route would look like alongside it.
Step by step
How Do You Weigh the Risks Before You Consent?
Work through six checks before you sign anything. Have the risk section read aloud, look the study up yourself, separate known risks from unknown ones, calendar every visit, ask who pays for what, and take the document to your own oncologist. An hour of this settles most of the fear.
-
Ask for the risk section to be read to you out loud
Consent must be given in a language you understand. Ask the study team to go through the risk section line by line, in that language, and to say which risks have actually been seen so far.
-
Look the study up on the CTRI register yourself
Trials run in India must be registered prospectively with the Clinical Trials Registry – India, maintained by ICMR's National Institute of Medical Statistics. The public entry names the intervention, the comparator and the study design.
-
Separate what is known from what is not yet known
The earlier the phase, the less is settled about side effects and dose. Ask which reactions have been reported in people so far, and which are theoretical. An investigational drug is under study precisely because its place is unsettled.
-
Put every visit on a calendar before you decide
Write down the screening window, each cycle, each protocol scan and the follow-up period. Add travel time and an attendant's time. The schedule, not the drug, is what most families underestimate.
-
Ask what happens if it does not work, and who pays for what
Ask for the next line of treatment in writing, and for an itemised list of what the sponsor covers. Free medical management for a trial-related injury is a duty under the New Drugs and Clinical Trials Rules, 2019; an unrelated illness is not covered.
-
Take the consent document to your own oncologist before signing
A second reading by the doctor who knows your reports is the most useful step on this list. No deadline on a consent form matters more than understanding what you are agreeing to.
Consent is a process, not a signature. The document must be in a language you understand, you may take it home, and you may ask for it again in simpler words. If a study team is reluctant to put an answer in writing, that reluctance is itself an answer. Details described here are indicative, as of August 2026.
The costs nobody lists
Which Risks Are Financial Rather Than Medical?
The investigational drug is usually supplied by the sponsor, but a trial is not free of cost. Travel to the trial centre, an attendant’s time, lost earnings and any care outside the protocol are normally yours. Ask for an itemised list of what the sponsor covers before consenting.
- The protocol defines what is covered — usually the investigational drug and the tests the study itself requires. Ask for that list in writing.
- Trial-related injury has a legal answer — free medical management is a sponsor duty under the New Drugs and Clinical Trials Rules, 2019.
- An unrelated illness is not covered by it — that falls back to your usual insurance or health scheme, exactly as it would off study.
- Travel and stay are the hidden line item — a fixed protocol calendar in another city is the cost most families underestimate.
- Check cover before you start, not after — insurance and scheme cover can behave differently for study-related items, so ask your insurer or TPA in advance.
- No CION rate applies to an investigational drug — anything quoted for a study comes from that study, and every figure here is indicative, as of August 2026.
A trial is not the only access route worth asking about. Where a medicine is approved but out of reach, a named-patient or compassionate-use request is a separate pathway with its own rules, set out in Compassionate Use and Named Patient Access. It is worth raising in the same conversation.
Go in with the questions already written down. The risks above turn into a short list of things to ask the study team, collected in Questions to Ask Before Joining a Trial. And settle the exit before you take the entrance, because what happens to your treatment when a study closes is the part families ask about too late — that is covered in What Happens When a Trial Ends?.
Before you decide
Know the Risks Before the Consent Form Is in Front of You
Tell us what has been proposed. We will go through the downside honestly and be clear about what a trial can and cannot do for your situation.
Real Stories. Real Voices.
15,000+ patients chose CION. Hear from them directly.
These aren't paid endorsements or written reviews. These are video testimonials from real patients and families — recorded on their own phones, in their own words. Pick any one. Watch it. Then decide.
4.8★800+ Google reviews
50+video testimonials
15,000+patients treated
Read all 800+ reviews on Google
Start Your Story. Book Free Consultation.
Common questions
Risks of an Immunotherapy Trial: Your Questions Answered
What are the real risks of joining an immunotherapy clinical trial?
Four risks are real and worth naming. First, the side-effect profile of an investigational drug may still be incomplete, so a reaction can appear that the protocol did not anticipate. Second, the schedule is heavier than routine care: screening tests, bloods before every cycle and scans on fixed protocol dates. Third, in a randomised study you may be assigned to the comparison arm rather than the investigational one. Fourth, the treatment may simply not help you, because no benefit is established for an investigational drug. Every one of these is set out in the participant information sheet and the informed consent document before you agree to anything.
Does a clinical trial mean extra visits, scans and blood tests?
Yes, almost always. A trial adds a screening window with imaging, an ECG, detailed bloods and often a tissue sample before eligibility is even confirmed. After that the protocol sets a fixed calendar: bloods before each cycle, longer visits, and response scans on protocol dates rather than only when your doctor would otherwise order them. Some protocols also ask for a repeat research biopsy, which is a procedure with its own risk, so ask whether it is optional. Follow-up visits and calls usually continue for a defined period after treatment ends. Put the whole calendar on paper, including travel and an attendant's time, before you decide.
What happens if the trial treatment does not work?
You come off the study and move to the next standard option. Disease progression is a defined reason for a study to stop your participation, and it is planned for in the protocol rather than being an unexpected event. Coming off a study does not remove your right to be treated at that centre, and your own oncologist should be told the same week. Ask two questions before you consent: what the next line of treatment would be, and who would provide it. Ask for both answers in writing. Also ask whether continued supply of the investigational drug is possible once the study closes, because that is not assured.
Who pays if a trial causes a side effect?
Under the New Drugs and Clinical Trials Rules, 2019, the sponsor must provide free medical management for an injury or side effect related to the trial, and compensation is determined under that framework where an injury is attributed to the study. An illness unrelated to the trial is not covered by it, and falls back to your usual insurance or health scheme. The protocol also defines which tests and visits the sponsor pays for. Travel, stay, an attendant's time and lost earnings are normally yours. Ask for an itemised list of what is covered before you consent. Figures and arrangements described here are indicative, as of August 2026.
Can you leave a trial once you have started?
Yes. Participation is voluntary at every point, and you may withdraw at any time, for any reason, without giving one. Withdrawal does not remove your right to standard treatment at that centre, and it should not change how you are treated by the team. Tell the study team and your own oncologist in the same conversation, because stopping an investigational drug sometimes needs a planned taper or a safety follow-up period rather than an abrupt halt. Ask what happens to the samples and data already collected, and ask for the withdrawal to be recorded in writing so there is no confusion later.
Does CION enrol patients into immunotherapy clinical trials?
This page is information, not recruitment. Nothing on it is an offer of a place on any study, no enrolment can be assured by anyone, and no benefit is claimed here for any investigational treatment. CION Cancer Clinics administers approved immunotherapy as day care at its centres, and coordinates response-assessment PET-CT at partner imaging centres rather than owning them. CION does not provide CAR-T or other cell therapies; where a cell-therapy study is what is under discussion, that is a referral to a centre that runs it. What a consultation can do is read the risk section of a consent document with you and give a straight view on whether a trial is a sensible option for your diagnosis.